126 related articles for article (PubMed ID: 1929309)
1. Treatment of experimental cryptococcosis with SCH 39304 and fluconazole.
Negroni R; Costa MR; Finquelievich JL; Iovannitti C; Agorio I; Tiraboschi IN; Loebenberg D
Antimicrob Agents Chemother; 1991 Jul; 35(7):1460-3. PubMed ID: 1929309
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of six antifungal treatments in an experimental model of murine cryptococcosis.
Bava AJ; Negroni R
Eur J Epidemiol; 1992 May; 8(3):422-6. PubMed ID: 1327864
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.
Hata K; Kimura J; Miki H; Toyosawa T; Moriyama M; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2243-7. PubMed ID: 8891122
[TBL] [Abstract][Full Text] [Related]
4. Treatment of cryptococcal meningitis in mice with fluconazole.
Palou de Fernandez E; Patino MM; Graybill JR; Tarbit MH
J Antimicrob Chemother; 1986 Aug; 18(2):261-70. PubMed ID: 3019986
[TBL] [Abstract][Full Text] [Related]
5. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
[TBL] [Abstract][Full Text] [Related]
6. Lanoconazole, a new imidazole antimycotic compound, protects MAIDS mice against encephalitis caused by Cryptococcus neoformans.
Furukawa K; Sasaki H; Pollard RB; Suzuki F
J Antimicrob Chemother; 2000 Sep; 46(3):443-50. PubMed ID: 10980172
[TBL] [Abstract][Full Text] [Related]
7. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans.
Hossain MA; Maesaki S; Mitsutake K; Kakeya H; Sasaki E; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1999 Dec; 44(6):827-9. PubMed ID: 10590286
[TBL] [Abstract][Full Text] [Related]
8. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome.
Sugar AM; Saunders C
Am J Med; 1988 Oct; 85(4):481-9. PubMed ID: 2845779
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of SCH39304 in murine cryptococcosis.
Restrepo BI; Ahrens J; Graybill JR
Antimicrob Agents Chemother; 1989 Aug; 33(8):1242-6. PubMed ID: 2552903
[TBL] [Abstract][Full Text] [Related]
10. In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent.
Tanio T; Ichise K; Nakajima T; Okuda T
Antimicrob Agents Chemother; 1990 Jun; 34(6):980-4. PubMed ID: 2203310
[TBL] [Abstract][Full Text] [Related]
11. A case of fluconazole, voriconazole-resistant Cryptococcus neoformans isolated from and immunocompetent patient.
Mandras N; Roana J; Tullio V; Allizond V; Banche G; Scalas D; Fucale G; Cuffini AM
J Chemother; 2011 Dec; 23(6):379-80. PubMed ID: 22233828
[No Abstract] [Full Text] [Related]
12. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice.
Troke PF; Andrews RJ; Marriott MS; Richardson K
J Antimicrob Chemother; 1987 May; 19(5):663-70. PubMed ID: 3038824
[TBL] [Abstract][Full Text] [Related]
13. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis.
Clemons KV; Brummer E; Stevens DA
Antimicrob Agents Chemother; 1994 Mar; 38(3):460-4. PubMed ID: 7911289
[TBL] [Abstract][Full Text] [Related]
14. New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformans
Lu RY; Ni TJ; Wu J; Yan L; Lv QZ; Li LP; Zhang DZ; Jiang YY
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31791946
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
[TBL] [Abstract][Full Text] [Related]
16. Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent.
Sugar AM; Picard M; Noble L
Antimicrob Agents Chemother; 1990 May; 34(5):896-8. PubMed ID: 2360825
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis.
Santos JR; César IC; Costa MC; Ribeiro NQ; Holanda RA; Ramos LH; Freitas GJ; Paixão TA; Pianetti GA; Santos DA
Eur J Pharm Sci; 2016 Sep; 92():235-43. PubMed ID: 27235581
[TBL] [Abstract][Full Text] [Related]
18. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients.
Stern JJ; Hartman BJ; Sharkey P; Rowland V; Squires KE; Murray HW; Graybill JR
Am J Med; 1988 Oct; 85(4):477-80. PubMed ID: 2845778
[TBL] [Abstract][Full Text] [Related]
19. Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing.
Lortholary O; Nicolas M; Soreda S; Improvisi L; Ronin O; Petitjean O; Dupont B; Tod M; Dromer F
J Antimicrob Chemother; 1999 Jun; 43(6):817-24. PubMed ID: 10404321
[TBL] [Abstract][Full Text] [Related]
20. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.
Perfect JR; Wright KA; Hobbs MM; Durack DT
Antimicrob Agents Chemother; 1989 Oct; 33(10):1735-40. PubMed ID: 2556078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
